Melanoma II Flashcards
1
Q
Biomarker that correlates to disease activity in melanoma
A
LDH
2
Q
First line for BRAF mutant in general
A
Immunotherapy
3
Q
What are the MEK inhibitors
A
- trametinib
- binimetinib
- cobimetinib
4
Q
Initial branch point in initial systemic therapy decision for BRAF mutant
A
IF indicators of aggressive disease present (liver mets, symptomatic, high LDH), then nivo ipi preferred
5
Q
Caveats with IO for metastatic melanoma
A
- responses may develop slowly
- patients may have transient worsening of disease before disease stabilizes or tumor regresses
- delayed responses are common with ipi-containing regimens
6
Q
What pathway is BRAF in
A
MAPK
7
Q
Prevalence of BRAF mutations in melanoma
A
50%
8
Q
Why are MEK inhibitors added to BRAF inhibition?
A
- reduces resistance and decreases cutaneous toxicity seen with single-agent BRAF inhibition
- also improved PFS and OS
9
Q
What are the BRAF inhibitors
A
- dabrafenib
- vemurafenib
- encorafenib
10
Q
targeted therapy for KIT
A
imatinib
11
Q
CNS penetration of targeted therapy in melanoma
A
Good
